ReviewProtein and peptide letters2024
The Role of TGFBR3 in the Development of Lung Cancer.
Review in Protein and peptide letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Integrated machine learning risk model for predicting radiation pneumonitis in lung cancer patients with interstitial lung disease.Annals of medicine · 2026Article
- Terpenoids as modulators of autophagy-senescence crosstalk in lung cancer.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Pattools‑implemented methylation vector analysis reveals aberrant subtype‑specific methylation in lung cancer across tissue and plasma cfDNA.Clinical and translational medicine · 2026Article
- miR-335-3p acts as a tumor suppressor in esophageal squamous cell carcinoma and predicts favorable prognosis.Hereditas · 2026Article
- ALDH18A1 silencing inhibits lung adenocarcinoma progression through mitochondrial dysfunction and PPAR signaling pathway activation.Biology direct · 2026Article
- The Wnt receptor Frizzled3 (FZD3) drives aggressive phenotypes in small cell lung cancer.Respiratory research · 2026Article
- Single-cell profiling of tumor lineage plasticity and the immune microenvironment in transformed small cell lung cancer.Journal of translational medicine · 2026Article
- Prognostic model of immune -related immune models of ANLN single gene based on TCGA lung adenocarcinoma database.Discover oncology · 2026Article
- A prognostic nomogram for overall survival in patients with driver-gene-negative lung adenocarcinoma and its biological basis.Discover oncology · 2026Article
- The role of PCMT1 in prognosis tumor immune microenvironment and therapeutic responses across cancers.Discover oncology · 2026Article
- TGFBR3 regulates the expression of FATP2-ACSL1 axis related proteins and accompanies changes in the migration and invasion ability of lung cancer cells.Frontiers in oncology · 2026Article
- Identification of PD-1-Related Genes as Prognostic Biomarkers in Lung Adenocarcinoma.Human mutation · 2026Article
- Research progress on the characteristics and functions of m6A modification in lung cancer tumor stem cells.American journal of cancer research · 2026Review
- Decoding anoikis-related genes in lung adenocarcinoma brainmetastasis via single-cell RNA sequencing: CD44-mediated functions.BMC cancer · 2025Article
- Construction and validation of a lung adenocarcinoma prognostic model based on neutrophil extracellular traps and oxidative stress-related genes.European journal of medical research · 2025Article
- Guanylate-binding proteins score and a CBFA2T3-included risk model define immune microenvironment and chemosensitivity in lung adenocarcinoma.European journal of medical research · 2025Article
- Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2025Article
- Role of signaling pathways in lung cancer development and advances in targeted therapies (Review).Oncology letters · 2025Review
- A novel risk model incorporating 4 mitochondrial unfolded protein response-related genes to predict the prognosis, gene mutation landscape, and immunotherapy response in lung adenocarcinoma.European journal of medical research · 2025Article
- Influence of stage-specific and location-related intratumoral microbiota on prognosis and metabolic reprogramming in non-small cell lung cancer.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The Transforming Growth Factor-β (TGF-β) mediates embryonic development, maintains cellular homeostasis, regulates immune function, and is involved in a wide range of other biological processes. TGF-β superfamily signaling pathways play an important role in cancer development and can promote or inhibit tumorigenesis. Type III TGF-β receptor (TGFBR3) is a co-receptor in the TGF-β signaling pathway, which often occurs with reduced or complete loss of expression in many cancer patients and can act as a tumor suppressor gene. The reduction or deletion of TGFBR3 is more pronounced compared to other elements in the TGF-β signaling pathway. In recent years, lung cancer is one of the major malignant tumors that endanger human health, and its prognosis is poor. Recent studies have reported that TGFBR3 expression decreases to varying degrees in different types of lung cancer, both at the tissue level and at the cellular level. The invasion, metastasis, angiogenesis, and apoptosis of lung cancer cells are closely related to the expression of TGFBR3, which strengthens the inhibitory function of TGFBR3 in the evolution of lung cancer. This article reviews the mechanism of TGFBR3 in lung cancer and the influencing factors associated with TGFBR3. Clarifying the physiological function of TGFBR3 and its molecular mechanism in lung cancer is conducive to the diagnosis and treatment of lung cancer.
Indexed as
Identifiers
39092729What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.